• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Scandidos

0.86 SEK

0.00 %

Less than 1K followers

SDOS

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
0.00 %
-12.24 %
-12.07 %
-27.73 %
-23.89 %
-39.01 %
-61.95 %
-78.61 %
-93.78 %

Scandidos operates in the medical technology sector. The company offers products and systems for quality assurance of advanced radiation therapy for cancer. The systems analyze the radiation dose before and during ongoing radiation treatment. The company was founded in 2002 and the first product was launched in 2006. Since its inception, Scandidos has delivered products to radiation therapy clinics on a global level. The head office is located in Uppsala.

Read more
Market cap
49.03M SEK
Turnover
34.99K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
16.6.
2026

Extraordinary general meeting '27

17.6.
2026

Annual report '26

17.9.
2026

Interim report Q1'27

Press release5/15/2026, 6:00 AM

ScandiDos Unveils Delta4 SRS Pro at ESTRO 2026: Setting a New Standard for Stereotactic QA

Scandidos
Regulatory press release5/6/2026, 12:00 PM

Anders Murman appointed Acting CEO of ScandiDos

Scandidos
Press release11/21/2024, 9:20 AM

ScandiDos Expands with New Reference Center in Madrid, Spain

Scandidos

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release4/18/2024, 11:00 AM

Successful user meeting in Madrid highlights ScandiDos' innovative solutions

Scandidos
Regulatory press release12/20/2023, 8:03 AM

ScandiDos receives orders worth €478 000 from China

Scandidos
Regulatory press release11/30/2023, 7:15 AM

ScandiDos AB changes Certified Adviser and liquidity provider to Carnegie Investment Bank AB (publ)

Scandidos
Regulatory press release11/29/2023, 3:34 PM

ScandiDos achieves EU Medical Device Regulation certification for the Delta4 Phantom+ product line

Scandidos
Regulatory press release6/28/2023, 8:55 AM

ScandiDos receives orders worth €290 000 from China

Scandidos
Press release5/13/2023, 8:00 AM

ScandiDos and IBA Dosimetry deepen strategic alliance!

Scandidos
Regulatory press release3/14/2023, 12:00 PM

ScandiDos receives an order worth €263 000 from China

Scandidos
Press release2/23/2023, 7:30 AM

ScandiDos sees growing demand for patient-specific QA in Chinese market

Scandidos
Regulatory press release11/1/2022, 12:50 PM

ScandiDos receives an order of € 377 500 from Japan

Scandidos
Press release9/2/2022, 12:30 PM

ScandiDos’ directed share issue completed

Scandidos
Regulatory press release8/30/2022, 4:00 PM

ScandiDos has completed a directed share issue of 4,150,000 shares at a subscription price of SEK 3 per share

Scandidos
Regulatory press release2/25/2022, 7:50 AM

ScandiDos launches Delta4 Insight which is immediately available to sell to customers in Europe and parts of Asia.

Scandidos
Regulatory press release2/16/2022, 7:00 AM

ScandiDos Celebrates 20th Anniversary

Scandidos
Regulatory press release3/4/2021, 3:36 PM

ScandiDos: Leading centers all over the world select Scandidos' Delta4 Phantom+ MR for their MR-linac programs

Scandidos